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Human papillomavirus (HPV) is a common viral infection worldwide associated with a variety of cancers. The
integration of the HPV genome in these patients causes chromosomal instability and triggers carcinogenesis. The
aim of this study was to investigate the HPV-16 genome physical status in four major cancers related to HPV
infection. Formalin-fixed paraffin-embedded blocks from our previous projects on head and neck, colorectal,
penile, and cervical cancers were collected, and HPV-16–positive specimens were used for further analysis. The
DNA extraction copy number of E2 and E7 genes was calculated by qualitative real-time PCR method. Serially
diluted standards that were cloned in PUC57 plasmid were used. Standard curve and melting curve analysis was
used for quantification. Of the 672 specimens studied, 76 (11.3%) were HPV-16 positive. We found that 35.6% (16/
45) were integrated. Statistical analysis showed that there were significant correlations between integration of
HPV-16 and cervical cancer end-stage carcinogenesis (P b .0001), episomal form, and ASCUS lesions (P = .045).
Significant correlation in penile cancer patients was seen between the episomal form and high-grade cancer stage
(P = .037). Integration is a major factor in the carcinogenesis mechanism of HPV and has different prevalence in
various cancers with a higher rate in progression except in penile cancer.
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ancer is one of the major public health challenges with a high mortality
orldwide. Human papillomavirus (HPV) is a major cause of some
man cancers such as cervical, penile, colorectal, esophagus, oropha-
ngeal, and head and neck cancers [1–4]. The risk of malignancy in
PV-positive cases is related to infection with specific types of HPVs
,5].HPVs are of numerous types (≥100), and they are divided into two
ajor groups: high risk (HR) and low risk (LR) [6,7]. The HR types are
ore often detected in association with cancers such as cervical cancer.
he major HR types includeHPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
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her types such as 26, 53, and 66 are defined as probable high-risk types,
d 69, 71, and 74 are defined as unknown-risk types [8,9]. Over 40
PV types have been detected in genital tract infections, and 12 of
em are related to carcinogenesis.HPV-16 is responsible for about 60%
cervical cancers [10].
It seems that HPV DNA of some HR types such as 16, 18, and 31
cancerous tissue has been integrated to host genome and causes
gher production of cancerous cells [11,12]. In HPV oncogenesis, it
highly accepted that, in the neoplastic lesions, HPV genome is in
e integrated form, and in the vegetative cycle inside differentiated
ithelial cells of benign lesions, it is in an episomal form. In the
tegrated form, the viral genome self-replication has been inter-
pted [13–15]. In the cancerous cells, HPV genes with E6, E7, and
CR (long control region) have been reported to integrate with the
st genome, and the other viral genes are removed. One of the roles
these viral regions is the disruption in the functioning of the major
llular tumor suppressor genes such as Rb and p53; consequently,
controlled cell growth occurs [13,14].
The frequency of HPV genome integration varies based on several
sk factors; the HPV types, specific cancers, and other personal or
ographical factors could influence the genome integration [16–19].
or instance, HPV-16 integration has been reported to vary from
% to 43% in oropharyngeal cancers, with the occurrence in 50%,
%, and 100% of the Japanese, Pakistani, and Colombian
ophageal cancer populations, respectively [17,20].
The determination of HPV genome status in cancerous and
ecancerous lesions is very important in tumor progress prognosis
d estimation of survival or response to therapy in these patients
5,17,21,22]. Furthermore, in the HPV mix infection, there are no
equate data about the HPV genome status.
In this regard, we aimed to design a preliminary study of HPV-16
nome status investigation in Iranian patients suffering from head
d neck squamous cell carcinoma (HNSCC) and colorectal, cervical,
d penile cancers.re
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atients
Patients were selected from our previous projects onHPV survey in
fferent cancers including cervical cancer [23], HNSCC [24], and
lorectal and penile cancer (not published) (n=672). The patients
ere referred to the referral hospitals affiliated to Iran University of
edical Sciences, Tehran, Iran. For the HPV detection, INNOLiPA
PV Genotyping assay and PCR-sequencing methods were used.
he included patients had a positive result forHPV-16, and some had
mixed infection by other types of HPVs.
thics Statement
The study protocol conformed to the ethical guidelines of the 1975
eclaration of Helsinki as reflected in the prior approval by the
stitution's human research committee. A written, informed consent
as obtained from each patient included in the study. All human
bjects were adult, and Institutional Review Board approval code
as IR.IUMS.FMD.REC 1396.92215402.
ampling
In this study with a retrospective design, the archived formalin-
xed paraffin-embedded (FFPE) blocks were collected from HNSCCd cervical, colorectal, and penile cancer populations [23,24].
linical databases and patient health records were used for retrieving
thological and clinical data fromMarch 2011 to January 2017. The
FPE blocks were fixed in 10% buffered formalin before paraffin
bedment, according to the documentation of the tissue repository.
NA Extraction
A thin 20-μm tissue section was obtained from the blocks, and
paraffinization was performed with xylene. Then, series of distilled
ater and graded ethanol solutions were used for rehydration,
cording to previous works [2,24,25]. The DNA purification was
rformed by using QIAamp DNA FFPE Tissue Kit (QIAGEN,
ilden, Germany), according to the manufacturer's protocol.
anoDrop ND-1000 (Thermo Fisher Scientific Inc., Waltham,
A) spectrophotometry was used for the evaluation of the isolated
NA. The purified DNA was kept at −20°C.
hysical Status of HPV DNA
In the integrated form of HPV DNA, the E6, E7, and LCR
gions were found, and the other HPV genes were removed. E2 and
6 or E7 genes quantification is the way to evaluate the HPV
tegration [13,14,26]. In this regard, by the quantitative real-time
CR (qRT-PCR) method, the viral loads of these genes (E2 and E6/
7) can be counted separately to distinguish the episomal, integrated,
a mixture of the two forms. In this study, we used the E2:E7 ratio
define the HPV-16 genome status. If the E2:E7 ratio was 0, the
nome was in an integrated form; if N1, it was episomal; and if N0
d b1, it was a mix of the two forms [9,13,27].
eal-Time PCR Assay
The Rotor-Gene-Q 6000 thermocycler (Corbett, Australia) was
ed for HPV-16 E2 and E7 quantification. The total volume of the
action mix was 15 μl that was composed of 7.5 μl of 2× Amplicon
I mix (Odense M, Denmark), 0.5 μl of each forward and reverse
imers corresponding to 0.5-μM concentration, and 3 μl each
mple or control corresponding to 0.2 to 0.5 μM concentration, and
st of the total volume was obtained by adding distilled water.
PV16-E2 gene forward primer was 5′-TGC CAA CGT TTA AAT
TG TG-3′ (2767-2786), reverse primer was 5′-CGC ATG AAC
TC CCA TAC TT-3′ (3298-3318), and the amplicon length was
1 base pairs; HPV16-E7 gene forward primer was 5′-TGC AAC
AG AGA CAA CTG AT-3′ (605-624), reverse primer was 5′-TGT
TA CGT GTG TGC TTT GT-3′ (768-787), and the amplicon
ngth was 183 base pairs [13]. The E7 gene was heated at 95°C for 5
inutes followed by 40 cycles at 95°C for 30 seconds and 60°C for 30
conds, and acquiring was in the annealing/extension step. The E2
ne was heated at 95°C for 5 minutes followed by 45 cycles at 95°C
r 30 seconds, 58°C for 30 seconds, and 72°C for 30 seconds, and
quiring was in the extension step. Melting curve program (50°C-
°C with a heating rate of 2°C per second and a continuous
orescence measurement) was used.
T-PCR standardization and Interpretation
Full-length HPV-16 E2 and E7 genes were cloned with PUC57
asmid as a standard control for quantification.Cloningwas done using a
mmercially available cloning system (TACloning kit of Invitrogen, San
iego, CA) according to manufacturer’s instructions. The serial dilution
anner was used for each gene, andDNase RNase-free water was used as
e solvent. Efficient standard curve (E = 0.95-1.05) of standards was used
r further quantification.
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Table 1. Descriptive Summary of HPV Survey Studies (n=672)
HNSCC CrCa PeCa CxCa
HPV16+ Total HPV16+ Total HPV16+ Total HPV16+ Total
Total (%) 2 (1.3) 156 (23.7) 3 (4.5) 66 (10) 6 (54) 11 65 (14.9) 436 (66.2)
Men (%) 2 (1.6) 121 (77.6) 2 (66.7) 38 (57.6) 6 () 11 0 0
Women (%) 0 35 (22.4) 1 (33.3) 28 (42.4) 0 0 65 (14.9) 436 (100)
Mean age±SD 65.5±12.6 60.5±12.6 64.3±13.2 59.3±14.4 35.0±5.5 35.8±5.7 38.4±13.6 35.3±10.1
Range 54-77 28-86 50-76 27-85 28-40 26-44 23-62 18-73
Other HPVs a - - - - - - 25 (38.5) 198 (45.4)
a Co-infected with other HPVs. HNSCC, head and neck squamous cell carcinoma; CrCa, colorectal cancer; PeCa, penile cancer; CxCa, cervical cancer; SD, standard deviation.
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SPSS software version 22 was used for statistical analyses of
atomic and demographic variables. The P values more than .05
ere not regarded as statistically significant.
esults
articipants
Based on the previous HPV surveys (n = 672) on patients with
lorectal cancer (n = 66), HNSCC (n = 156), cervical cancer (n =
6), and penile cancer (n = 14), we detected 76 (11.3%) HPV-16
sitive specimens by INNOLiPA HPV genotyping assay and PCR-
quencing–based methods. Brief details of the HPV investigations
e shown in Table 1.
Totally, 45 HPV-16 positive specimens, based on the clinical
atus and availability of the samples, were randomly selected for
nome status analysis. Brief results of the cytological and histological
alysis of the 45 HPV-16 positive cases are shown in Table 2.
T-PCR
Standard curves were drawn for HPV E7 and E2 genes by using
andards diluted five to seven times. The efficiency of each E7 and
2 standard curve was 97% and 117%, respectively. The melting
rve analysis confirms our standard interpretations (Supplementary
gure 1). During 40 real-time PCR amplification cycles, there were
primer-dimer generation.
Then, a total of 45 HPV-16 specimens were subjected to qRT-
R, and the viral load of each of the E2 and E7 genes was reported
sed on the melting analysis and appropriate positive (standard) and
gative controls (Supplementary Figure 2). A negative control (water
DNA extracted from previous works that was negative for HPV)
as used in each run, and it did not have nonspecific yielded
orescence signals above the background.
In general, 16 (35.6%) of the 45 specimens had undetectable levels
r one or more of the E2 gene, and all of them had E7 viral loadble 2. Pathologic Characteristics of our HPV-16–Positive Cases (n=45)
HNSCC (%) CrCa (%) PeCa (%) CxCa (%)
igh grade 1 (50) 1 (33.3) 2 (33.3) -
w grade 1 (50) 2 (66.7) 4 (66.7) -
SCUS - - - 8 (23.5)
LSIL - - - 6 (17.6)
HSIL - - - 11 (32.3)
ancerous - - - 9 (26.5)
Total 2 (4.4) 3 (6.7) 6 (13.3) 34 (75.6)
CUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous
raepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.
Fi
pa
conging from 1,270,709,529 to 1098 copies/μL. For the E2 gene, it was
,193,565 copies/μL to undetectable levels. The E2:E7 ratio was
lculated for the interpretation of the viral genome status (Figure 1). The
PV-16 integrated form was detected in 35.6% (16/45), episomal form
24.4% (11/45), and mixed form in 40% (18/45) of the specimens.
PV-16 physical genome status investigation details by pathologic status
specimens are shown in Table 3.
atistical Analysis
The analysis of the different variables showed that there was a
gnificant association between the integration of HPV-16 and end
ages of carcinogenesis (higher-stage lesions (HSIL) and cancerous
sions [n = 9]) (P b .0001). This finding suggests that the integration
HPV-16 in high-grade lesions in cervical cancer is more common
an the other types of lesions, about 69.2% (9/13) in our study.
here was a significant association between HPV-16 episomal form
d ASCUS lesions (P = .045). This highlights the primary stage of
PV infection in these patients in which the HPV genome is
isomal in the vegetative stage. The analysis of variables from
nile cancer patients showed a significant result only in the
rrelation of the episomal form with high-grade cancer stage (P =
37). The analysis of age with the genome status showed that there
as no significant relationship between age and integration of HPV-
genome. The results for the other variables were not significant
N .05).gure 1. Frequency of HPV-16 genome status in our 45 cancerous
tients. HNSCC, head and neck squamous cell carcinoma; CrCa,
lorectal cancer; PeCa, penile cancer; CxCa, cervical cancer.
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Table 3. Demographic and Pathologic Genome Status of Our Included Patients (n=45)
Genome
Status
No
(%)
Sex Age Mean
± SD
Grade Pathologic Feature
High Low ASCUS LSIL HSIL Cancerous
HNSCC Integrated 1 (50) Man 77 0 1 - - - -
Mixed 1 (50) Man 54 1 0 - - - -
CrCa Episomal 1 (33) Man 76 1 0 - - - -
Integrated 1 (33) Woman 67 0 1 - - - -
Mixed 1 (33) Man 50 1 0 - - - -
PeCa Episomal 3 (50) Men 32.0±6.9 3 0 - - - -
Integrated 1 (17) Man 40 1 0 - - - -
Mixed 2 (33) Men 35.5±2.1 1 1 - - - -
CxCa Episomal 7 (21) Women 30.7±3.4 - - 4 2 0 1
Integrated 13 (38) Women 29.6±3.9 - - 1 3 5 4
Mixed 14 (41) Women 31.1±10.5 - - 3 1 6 4
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PV is one of the common viral infections, affecting nearly 80
illion people currently in the United States (about 25% of the
pulation) [28,29]. There are several HPV-related cancers including
ncer of the cervix, vulva, vagina, penis, anus, rectum, tongue, and
nsils (oropharynx) as well as colorectal cancer [4,23,24,30–34]. The
st described prevention method for HPV infection is vaccination
5–37]. Oropharyngeal and penile cancers are HPV-related cancers
at are more prevalent in men and cervical cancer in women
8,28,29,38]. HPV genome integration plays a crucial role in HPV-
lated carcinogenesis and can trigger instability in the chromosomes
9,29]. The severity of the disease after integration of the HPV
nome increases and may cause a reduction in the viral load. The E6,
7, and LCR regions of the HPV genome have been reported to be
tegrated into the cancerous cells, and other genes such as E2 and E1
e eliminated [9,13,27]. The viral DNA of HR-HPVs such as HPV-
and HPV-18 often integrates into the host cell genome and causes
erexpression of E6 and E7 regions that disrupt cellular proto-
cogenes such as pRb and p53; consequently, it causes malignancy
1,39]. The HPV genome status can be used as a prognostic marker
HPV-associated cancers [15,17,21,22]. In this regard, we aimed to
vestigate the HPV-16 genome status in different HPV-related
ncers including HNSCC, colorectal, penile, and cervical cancer
ecimens which were positive forHPV-16 genome detected by using
NO-LiPA Genotyping and PCR-sequencing methods from the
evious studies [23,24]. Our study was designed to count the HPV-
E2 and E7 gene viral load using qRT-PCR [13]. Among the 45
PV-16 infected patient samples analyzed, we found that 11
4.4%) were episomal, 16 (35.6%) were integrated, and 18 (40%)
ere mixed form.
A study by Cheung et al. [13] showed that there were integrated,
isomal, and mixed forms in 32.4% (11/34), 32.4% (11/34), and
.3% (12/34) in European and 47% (31/66), 28.8% (19/66), and
.2% (16/66) in Asian HPV-16–positive cervical specimens,
spectively. They found the episomal form in 33.3% of CIN3 and
% of SCC lesions. They emphasized the challenges in the use of the
tegration status as an adjunctive marker in the management of
PV-positive patients. In the current study, qRT-PCR was designed
r viral load evaluation, and we found that 35.6% of our total
ecimens and 38% of our cervical specimens had integrated form of
PV-16 genome; furthermore, integration in HSIL lesions was
.4% (5/11), and in cancerous mass, it was 44.4% (4/9). The
atistics showed that there was a significant relationship between the
tegration of HPV-16 DNA in HSIL and cancerous vs. ASCUS and
SIL) that indicates a higher risk for these patients for cancerogression and chromosomal instability. Our study showed
fferences between the frequencies of HPV episomal form in cervical
ecimens similar to that described by Cheung et al. [13] (33% and
% vs. 5%). HPV episomal forms were seen in only 5% (1/20) of
e high-grade cervical cancer specimens (HSIL and cancerous) in our
udy, which is different from that reported in other studies. This
uld be due to the impact of other risk factors on the integration
atus of HPV, such as alcohol consumption or smoking. Meanwhile,
ere is evidence that indicates that the pure episomal form of HPV
sociates with some invasive cervical cancers [13,40,41]. This
sociation has not been proven by our study data. It may be due to
e cancer therapies that were used to suppress the tumor progression.
udies have also shown a substantial proportion of HPV genome
tegration in low grade and primary stage of HPV infection [13,42].
e detected 28.6% (4/14) integrated form in ASCUS/LSIL lesions
at were in the primary stages. The integration in early stages shows a
obable role of other risk factors such as smoking, alcohol
nsumption, or UV radiation.
A study by Liu et al. [43] of HPV-16–positive cervical carcinoma
ecimens showed integration in 63% (19/30). We found that the
erall integration frequency was 35.6% (16/45), and in cervical
ecimens, it was 38%. In patients with only cervical cancer, the
equency was 44.4% (4/9), which is different to that mentioned in
e report by Liu et al. [43]; this could be due to the environmental,
ral, or host factor effects. A study by Bodelon et al. [10] of 38 HPV-
–positive CIN3 (17/38) and cervical cancer (21/38) specimens
owed that there were 60.5% (23/38) integrated and 39.5% (15/38)
isomal form, respectively. The episomal form was detected in
.9% (9/17) and 28.6% (6/21) and the integrated form in 47.1%
/17) and 71.4% (15/21) of CIN3 and cancer patients, respectively.
he authors concluded that the instability of chromosomes in the
sence of integration might play a crucial role in facilitating
tegration. Our study showed that 24.4% (11/34) were episomal,
.6% (16/34) were integrated, and the rest of them were mixed
rm. These differences may be due to our pooled population of four
ncers and the presence of mixed form including episomal and
tegrated forms. In the pure cervical cancer specimens, the episomal
d integrated form frequency was 20.6% (7/34) and 38.2% (13/34),
hich by using pure HSIL and cancer patients became 5% (1/20) and
% (9/20), respectively. Our current study showed that the
tegration occurred more in high-grade and cancerous cervical
sions, 45% (9/20), and it was significant in higher-grade malignant
sions (HSIL and cancerous vs. ASCUS and LSIL). These findings
uld be related to the different populations or detection methods. It
simple to understand the higher prevalence of integration in the
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ese lesions.
The study by Castillo et al. [20] in Japan, Pakistan, and Colombia
the HPV genome status in patients with tonsil, tongue, other oral
ncers, and esophageal carcinoma reported HPV-16 genome
tegration in 60% (6/10), 80% (16/20), 95% (18/19), and 71%
7/24) and mixed form in 40% (4/10), 10% (2/20), 5% (1/19), and
% (5/24), respectively; episomal form in tongue mass was 10% (2/
) and in esophagus was 8% (2/24). This emphasizes the frequent
tegration of HPV-16 genome in SCCs of the oral cavity,
opharynx, and esophagus. Our study showed that the frequency
integration of HPV-16 genome in HNSCC patients is 50% (1/2),
is being seen in a patient with tonsil cancer. It confirms the findings
the study by Castillo et al. in three countries. Further study with a
rger sample size is needed to obtain comprehensive results. A study
Olthof et al. [44] in 75 patients with HPV-16–positive OSCC
alyzed for the physical status of the viral genome showed
tegration in 39% (29/75) and episomal form in 61% (46/75).
ur total integration frequency in four surveys is similar to this study,
t in HNSCC patients, it was 50%, and its differences could be due
the limited population in the present study.
The association of HPV with different cancers has been reported
equently. Colorectal cancer is one of the challenging issues, and its
sociation with HPV infection is under investigation [45,46]. In the
udy by Bernabe-Dones et al. [45] of 12 colorectal cancer patients
fected with HPV-16, the E2 gene evaluation for genome status by
sted PCR method found that the genome in all the specimens was
an integrated form. They conclude that the integration of HPV-16
nome into the host genome could be a proof of the probable role of
PV in colorectal carcinogenesis. In the present study, we used the
evious study (data not published) specimens that were HPV-16
sitive. In a preliminary study, we analyzed the three HPV-16
nomes in colorectal cancer for the physical status and found that
% (1/3) of them were in an integrated form, 33% (1/3) were
isomal, and 33% (1/3) were mixed. Based on the histological and
thological data, 67% (2/3) of the specimens were of high-grade
ncerous stage with episomal and mixed forms of HPV-16.
terestingly, integration was seen in low-grade cancerous tissue.
his indicates the probable role of HPV in the initial stages of
romosomal instability and its potential to trigger the neoplasia in
lorectal cancer patients, although there was no association between
e pathologic stage of cancer and the physical status of the HPV
nome. Further studies are required to clarify the subject.
Penile cancer is one of the major genital cancers in men that could
multifactorial, with smoking, phimosis, and poor hygiene being
me of them. Its association with HPV infection has been
vestigated, and its frequency has been reported to be 20% to
% [33,47,48]. The study by Djajadiningrat et al. [47] in 212
tients with penile cancer showed that they were infected with the
R HPV types with a frequency of 25%, and of them, 79% were
PV-16 types. Our previous study (data not published) showed
e presence of HPV-16 genome in 54% (6/11) of penile cancer
tients (6/11). Few studies have reported the HPV genome status in
ese patients. In the present study, we found the prevalence of the
tegrated form of HPV-16 in these patients to be 17% (1/6),
isomal form 50% (3/6), and mixed form 33% (2/6). It seems that
e episomal form of HPV is common in penile cancer patients, and
gh grade of penile cancer lesions has lower chromosomal instability
insertion of a foreign gene (HPV) compared with that in cervicalncer patients. This finding is different from our understanding
out carcinogenesis of HPV infection and needs further analysis for
tter comprehension.
Our study limitations were the lack of another confirmatory or
ore accurate method such as TaqMan qRT-PCR to calculate the
py numbers, although relative calculation facilitates our study. For
rther studies, we recommended using a larger number of specimens
d studying the other major HR HPV types’ behavior in the host
nome using more demographic data from the history and risk
ctors involved in the patients.
In conclusion, there is a significant risk of HPV integration in a
gher level of carcinogenesis compared with lower stages, although in
group of penile cancer specimens in this study, we found the
isomal form to be more common in higher grade of cancer. Higher
plication of cancerous and precancerous cells causes chromosomal
stability and could facilitate the deletion/insertion of foreign genes
ch as HPV genome. As we observed in a majority of higher grade of
ncerous lesions, the risk of HPV genome integration is inevitable,
though other environmental and personal risk factors should not be
glected. The mixed form of HPV genome at cancerous and
ecancerous levels declares the primary phase of pure integration in
e subsequent progressive stages.
Supplementary data to this article can be found online at https://
i.org/10.1016/j.tranon.2018.02.017.
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